Evidence map›Paper›PMID 22248301›Full record

SynthesisCardiovascular diabetology2012

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.

Michael E Cobble, Robert Frederich

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cardiovascular diabetology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02377388 (DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02377388 phase3completednot on this mapstarted 2017, after this paper: background citation

DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function

TypeinterventionalSponsorUniversity of Sao Paulo General HospitalRan2017 to 2020Enrolled74ConditionsPlatelet Aggregation During Acute Myocardial InfarctionArmssitagliptin OR saxagliptin, placebo
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021
    Review
  8. Pharmacological treatment of hyperglycemia in type 2 diabetes.The Journal of clinical investigation · 2021
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes.Clinical diabetes : a publication of the American Diabetes Association · 2014
    Article
  18. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.American journal of physiology. Heart and circulatory physiology · 2014
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Michael E CobbleCanyons Medical Center, Sandy, UT, USA. mcobble@canyonsmedical.com
Robert Frederich
Bristol-Myers Squibb (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular (CV) disease; however, conclusive evidence that glycemic control leads to improved cardiovascular outcomes is lacking. Saxagliptin is a potent, selective dipeptidyl peptidase-4 inhibitor approved as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Saxagliptin was evaluated in a series of phase III trials as monotherapy; add-on therapy to metformin, a sulfonylurea, or a thiazolidinedione; and as initial therapy in combination with metformin. Saxagliptin consistently improved glycemic control (as reflected by significant decreases in glycated hemoglobin, fasting plasma glucose, and postprandial glucose compared with controls) and was generally well tolerated. In these analyses, saxagliptin had clinically neutral effects on body weight, blood pressure, lipid levels, and other markers of CV risk compared with controls. A retrospective meta-analysis of 8 phase II and phase III trials found no evidence that saxagliptin increases CV risk in patients with T2DM (Cox proportional hazard ratio, 0.43; 95% CI, 0.23-0.80 for major adverse cardiovascular events retrospectively adjudicated). Instead, it raised the hypothesis that saxagliptin may reduce the risk of major adverse CV events. A long-term CV outcome trial, Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-THrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) is currently ongoing to determine whether saxagliptin reduces CV risk in T2DM.

Indexed as

AdamantaneCardiovascular DiseasesClinical Trials as TopicDiabetes ComplicationsDiabetes Mellitus, Type 2DipeptidesDipeptidyl-Peptidase IV InhibitorsDrug Therapy, CombinationEvidence-Based MedicineHumansPatient SafetyProportional Hazards ModelsRisk AssessmentRisk FactorsTreatment OutcomeAdamantaneDipeptidesDipeptidyl-Peptidase IV Inhibitorssaxagliptin

Identifiers

PMID22248301
PMCPMC3277488
OpenAlexW2133034433

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.